← Leaderboards
Sanjiv S Agarwala
University Of Pittsburgh At Pittsburgh
$60,067
Attributed
$60,067
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$60,067 · 5
By mechanism
M01$60,067 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Jennifer R Grandis$109,711,044
- John Munn Kirkwood$15,450,309
- Michael S. Diamond$85,358,908
- Candace S Johnson$18,922,226
- Francis E Lotrich$2,796,862
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectClinical ResearchNeoplasm /Cancer ChemotherapyNeoplasm /Cancer ImmunotherapyMelanomaPatient Oriented ResearchInterferon AlphaIntravenous AdministrationHead /Neck NeoplasmClinical Trial Phase IiiClinical Trial Phase IPharmacokineticsQuinazolinesAntineoplasticsSquamous Cell CarcinomaCombination Cancer TherapyCombination ChemotherapyDosageDrug Screening /EvaluationEpidermal Growth FactorGrowth Factor ReceptorsInterferonsInterleukin 2
Grant awards (10)
PH1 STDY EPIDERMAL GRWTH FCT REC TYROSINE KINASE INH COMBO W/DOCETAXEL$31,645
M01 · FY2005 · RR
PH II UCN-01 METASTATIC MELANOMA$8,327
M01 · FY2005 · RR
A Rand Study of Four Weeks High Dose IFN 2b in Melanoma$7,885
M01 · FY2004 · RR
PH1 Study EGFR Tyrosine Kinase Inhibitor w/ Docetaxel$6,614
M01 · FY2004 · RR
PH3, MC, OL, Surv/Safety Study of Head/Neck Carcinoma$5,342
M01 · FY2004 · RR
PHI Dose Escal. Study Eval Safety of Albuleukin$254
M01 · FY2004 · RR
FOUR WEEK HIGH DOSE INTERFERON A2B IN STAGE IIA MELANOMA$0
M01 · FY2002 · RR
FOUR WEEK HIGH DOSE INTERFERON A2B IN STAGE IIA MELANOMA$0
M01 · FY2002 · RR
FOUR WEEK HIGH DOSE INTERFERON A2B IN STAGE IIA MELANOMA$0
M01 · FY2001 · RR
FOUR WEEK HIGH DOSE INTERFERON A2B IN STAGE IIA MELANOMA$0
M01 · FY2000 · RR